Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial.
Kelly E, Greenland M, de Whalley P, Macaulay GC, Aley PK, Plested E, Koleva S, Cotton J, Kinch J, Madupuri T, Read RC, Ramsay M, Cameron C, Turner DPJ, Heath P, Connor P, Cathie K, Faust SN, Banerjee I, Man K, Shackley F, O' Riordan S, Owens S, Polychronakis T, Trari Belhadef H, Mujadidi Y, Singha A, Cantrell L, Clutterbuck E, Anslow R, James T, Hallis B, Matheson M, Chang L, Lambe T, Nguyen-Van-Tam JS, Snape MD, Minassian AM, Liu X.
Kelly E, et al.
J Infect. 2026 Jan;92(1):106663. doi: 10.1016/j.jinf.2025.106663. Epub 2025 Dec 1.
J Infect. 2026.
PMID: 41338394
Free article.
Clinical Trial.
Although recruitment ceased early, the sample size required to fulfil the primary objective was met. FINDINGS: 281 participants were recruited (mean age 14 years old, 57% female). ...
Although recruitment ceased early, the sample size required to fulfil the primary objective was met. FINDINGS: 281 participants were …